Subtype
Head and Neck Squamous Cell Carcinoma
CI-CAN-00002836HNSCC · SCCHNExplore in graph →
592 active trials6 approved drugs53 evidence items
- NCIt
- C34447
- OncoTree
- HNSC
- DOID
- 5520
- UMLS CUI
- C1168401
- MeSH
- D000077195
- Other
- 1 more code
Loading cancer entity…
Subtype
CI-CAN-00002836HNSCC · SCCHNExplore in graph →
Clinical trials
1,589 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (247)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03325465 | Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT03114280 | Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)(PICH) | withdrawn | Phase 1 / Phase 2 | 0 | Centre Antoine LacassagneOTHER | 1 | Apr 8, 2019 |
| NCT02993991 | Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity(PRIMED-001) | withdrawn | Phase 1 | 0 | University Health Network, TorontoOTHER | 1 | Dec 29, 2017 | clinicaltrials |
| NCT02211027 | Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA | withdrawn | Phase 1 | 0 | Robert FerrisOTHER | 1 | Sep 7, 2017 | clinicaltrials |
| NCT02593929 | Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer | withdrawn | Early Phase 1 | 0 | University of PittsburghOTHER | 0 | Jun 8, 2017 | clinicaltrials |
| NCT02567396 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Apr 24, 2017 | clinicaltrials |
| NCT02649530 | A Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma | withdrawn | Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 30, 2016 | clinicaltrials |
| NCT01820312 | A Phase II Study to Evaluate Low-Dose Fractionated Radiotherapy (LDFRT) | withdrawn | Phase 2 | 0 | University of ArkansasOTHER | 1 | Aug 8, 2016 | clinicaltrials |
| NCT00627835 | Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN) | withdrawn | Phase 1 | 0 | British Columbia Cancer AgencyOTHER | 1 | Jul 20, 2016 | clinicaltrials |
| NCT02119728 | Photodynamic Therapy With HPPH in Treating Patients With Squamous Cell Carcinoma of the Oral Cavity | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Apr 21, 2016 | clinicaltrials |
| NCT02143622 | Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients | withdrawn | Phase 1 / Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 21, 2016 | clinicaltrials |
| NCT01586182 | Stereotactic Boost for Oropharyngeal Squamous Cell Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 4, 2015 | clinicaltrials |
| NCT01953952 | Radiation Therapy and Cisplatin With or Without Surgery in Treating Patients With Stage III-IV Oropharyngeal Cancer | withdrawn | Phase 2 | 0 | Radiation Therapy Oncology GroupNETWORK | 1 | Mar 20, 2015 | clinicaltrials |
| NCT01133262 | Effectiveness in Head and Neck Cancer Detection Using Positron Emission Tomography (PET) Insert Device | withdrawn | — | 0 | Washington University School of MedicineOTHER | 1 | Mar 10, 2015 | clinicaltrials |
| NCT01718223 | Photodynamic Therapy Using Temoporfin Before Surgery in Treating Patients With Recurrent Oral Cavity or Oropharyngeal Cancer | withdrawn | N/A | 0 | Roswell Park Cancer InstituteOTHER | 0 | Sep 3, 2014 | clinicaltrials |
| NCT01728480 | Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 0 | Dec 11, 2013 | clinicaltrials |
| NCT00095641 | S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent or Persistent Head and Neck Cancer | withdrawn | Phase 2 | 0 | SWOG Cancer Research NetworkNETWORK | 0 | Nov 8, 2013 | clinicaltrials |
| NCT01674374 | Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 0 | May 15, 2013 | clinicaltrials |
| NCT00038038 | Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole | withdrawn | N/A | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 1, 2012 | clinicaltrials |
Data updated 23 days agoSource updated Apr 22, 2019source: clinicaltrials